Cerebral Circulation-Cognition and Behavior is an impactful journal published by Elsevier that focuses on the intersections of cerebral circulation, cognitive function, and behavioral science. Since its establishment in 2020, the journal has provided a vital platform for researchers and professionals in the fields of Behavioral Neuroscience, Biological Psychiatry, and Cognitive Neuroscience. With a current classification in the Q3 quartile across several neuroscience categories and a promising trajectory during its converged years (2020-2024), the journal highlights significant advancements in our understanding of the neural underpinnings of behavior. Although it is not open access, its commitment to quality research makes it an essential resource for anyone engaged in neurological, cognitive, and psychiatric studies. As discoveries in these fields continue to grow, Cerebral Circulation-Cognition and Behavior remains dedicated to disseminating influential findings that bridge the gap between cognition, behavior, and neural health.

Kardiologia Polska, the esteemed journal of the Polish Cardiac Society, has established itself as a vital resource in the field of cardiology and cardiovascular medicine since its inception in 1954. With an ISSN of 0022-9032 and an E-ISSN of 1897-4279, this journal serves as a platform for groundbreaking research and scholarly articles that contribute to the advancement of heart health. Although currently not an open access journal, it remains an essential reference for practitioners and researchers seeking to stay abreast of the latest developments in cardiovascular science. The journal reflects its scholarly depth through a Category Quartile of Q3 and a commendable Scopus ranking at the 48th percentile in its field. Published primarily in Poland, it caters to a global audience eager to explore comprehensive studies spanning clinical cardiology, innovative therapeutic approaches, and emerging cardiovascular trends. Join a thriving academic community by engaging with the invaluable insights and research contributions found within the pages of Kardiologia Polska.

THROMBOSIS AND HAEMOSTASIS is a prestigious journal published by GEORG THIEME VERLAG KG, dedicated to advanced research in the field of hematology. With an esteemed Impact Factor and recognized as Q1 in its category for 2023, the journal is regarded for its pivotal role in disseminating significant findings that contribute to our understanding of thrombosis and hemostasis. Since its inception in 1976, this journal has continuously published cutting-edge studies and reviews, making it a vital resource for researchers, healthcare professionals, and students alike. The journal’s commitment to high-quality research is reflected in its impressive Scopus Ranking of #18 out of 137 in Medicine - Hematology, placing it in the 87th percentile among its peers. Although not currently open access, THROMBOSIS AND HAEMOSTASIS remains an authoritative source for exploring novel therapeutic strategies and the latest scientific advancements in the field. Based in Stuttgart, Germany, this journal serves as a critical platform for sharing knowledge and fostering collaboration within the global hematology community.

International Heart Journal, published by INT HEART JOURNAL ASSOC, serves as a pivotal platform for research and discourse in the fields of cardiology and cardiovascular medicine. With its ISSN 1349-2365 and E-ISSN 1349-3299, this esteemed journal is based in Japan and is located at the University of Tokyo, Graduate School of Medicine, Department of Cardiovascular Medicine. Since its inception in 2005, International Heart Journal has blossomed into a respected publication with an impact factor that signifies its growing relevance, ranking in the Q3 category of both cardiology and miscellaneous medicine as of 2023. This journal not only disseminates vital research findings but also fosters collaboration among researchers and healthcare professionals. Notable for its Open Access options, it ensures the availability of its content to a broader audience, thereby enhancing knowledge transfer and innovation in cardiovascular care. With an ongoing commitment to improve clinical practice and patient outcomes, the journal continues to be an essential resource for those dedicated to advancing the understanding of heart health and disease.

Welcome to the JOURNAL OF VASCULAR RESEARCH, a reputable academic journal published by KARGER that has been a cornerstone of vascular research since 1964. With an ISSN of 1018-1172 and an E-ISSN of 1423-0135, this journal plays a vital role in disseminating cutting-edge research in the fields of Cardiology and Cardiovascular Medicine and Physiology. Currently categorized in the Q3 quartile for both disciplines, it ranks as #179 in Cardiology and #131 in Physiology according to Scopus, showcasing its significant contribution to the scientific community. Although the journal operates on a subscription basis, it strives to provide accessible content that informs and inspires researchers, professionals, and students alike. As the journal looks forward to its convergence in 2024, it continues to uphold its mission of advancing knowledge, fostering innovation, and encouraging collaboration within the dynamic realm of vascular research.

Current Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

Rational Pharmacotherapy in Cardiology, published by the SOC CARDIOLOGY RUSSIAN FEDERATION, stands as a crucial platform for advancing knowledge in the field of cardiology and pharmacology. Established as an Open Access journal in 2005, it allows for unrestricted access to research findings, fostering collaboration among researchers, clinicians, and students. The journal, with its ISSN 1819-6446 and E-ISSN 2225-3653, focuses on the intersection of rational pharmacotherapy and cardiovascular medicine, aiming to enhance treatment strategies and patient outcomes through evidence-based studies. Though currently positioned in the Q4 category in both cardiology and pharmacology rankings, its ongoing commitment to rigorous peer review and scholarly research ensures its relevance and growth in the scientific community. With a unique address in Moscow, Russia, the journal seeks to serve as a valuable resource for those dedicated to improving cardiovascular health and therapeutic practices worldwide, making it an essential read for professionals keen on the latest trends and discoveries in this vital area of medicine.

Vasa - European Journal of Vascular Medicine is a leading peer-reviewed journal dedicated to advancing the field of vascular medicine, published by HOGREFE AG in Switzerland. With a proud history dating back to 1972, this journal serves as a critical platform for researchers, clinicians, and healthcare professionals committed to enhancing knowledge and practice related to cardiovascular health and vascular disorders. Holding a notable Q2 ranking in the cardiology and cardiovascular medicine category, Vasa’s scholarly contributions reflect high-quality research and innovative insights that drive clinical applications. The journal provides essential access to original articles, reviews, and case studies, fostering a vibrant exchange of ideas within the vascular medicine community. Its Scopus rank of #159 out of 387 further underscores its impact, placing it confidently in the 59th percentile among its peers. Vasa is synonymous with rigorous academic standards and relevance, making it an invaluable resource for anyone seeking to stay at the forefront of vascular research and its clinical implications.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.